Contact Us |








dayanews emp


16 | Apr | 2014

Pluristem to Deliver Key Commercialization and Scientific Presentations at International Society for Cellular Therapy Conference 2014

Read more >


26 | Mar | 2014

UK’s Minister for Universities and Science, David Willetts & his Delegation Visit Pluristem Regarding UK-Israel Cooperation on Regenerative Medicine

Read more >

25 | Mar | 2014

Pluristem Scientists to Present a Poster on GvHD & Participate in a Panel Discussion at the BIRAX Regenerative Medicine Conference

Read more >

12 | Mar | 2014

Preclinical Results for Pluristem’s PLX-PAD Cells in Tendon Injury Presented at American Academy of Orthopedic Surgeons' Annual Meeting

Read more >

11 | Mar | 2014

Pluristem to Present at Barclays and RegenMed Financial Conferences

Read more >

About hp

Zami Aberman

Chairman and CEO


Zami Aberman

   From the CEO

Our vision at Pluristem Therapeutics inc. is to leverage our position as the global leader in placenta-based cell science to become the world’s leader in developing and manufacturing cell therapy products. We believe our cutting edge technology can become the standard of care for treating a host of inflammatory and ischemic conditions. We are in the process of achieving this vision by building a successful, winning team to maintain our standard of excellence in the research, development and production of cell therapies. 

We continue to develop our understanding surrounding the mechanism of action of PLacental eXpanded (PLX) cells. We then leverage this understanding towards the development of these cells for additional markets. Currently we are actively pursuing indications in the peripheral vascular, pulmonary, orthopedic, ob-gyn and hematology markets.

We also believe “the Process is the Product.” This reflects our view that the precise control of the entire process, from obtaining cells from the source, to delivery to the patient, is vitally important to the success of a cell therapy product. Part of the reason we are able to obtain this precision  in our cell expansion process is our exclusive ability to expand cells via our proprietary 3D technology. Combining this “Powered by Pluristem” fully automated process with our increasing knowledge of the placental cell is the powerful engine towards identifying additional products for new markets and indications.

Every engine needs a driver, which returns me to the key to success for achieving our vision: the team. Our team has the ability, integrity, commitment and courage to develop breakthrough cell therapies that can transform the treatment of certain diseases and deliver value to our  shareholders. 

Zami Aberman
Chairman and CEO 


Share Button comm

tech hp

Ohad Karnieli, Ph.D., MBA
VP Development & Manufacturing


Ohad Karnieli

The United States Food and Drug Administration (FDA) has reviewed Pluristem’s comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for the Company to manufacture these products in its new commercial-scale cell manufacturing facility.



Share Button comm

Clinical Program hp

Esther Lukasiewicz Hagai, M.D., Ph.D.
VP Clinical & Medical Affairs


Esther Lukasiewicz Hagai

Medical Key Opinion Leaders in Preeclampsia Join Pluristem’s Steering Committee:

Prof. James M. Roberts, M.D., University of Pittsburgh
Professor, Department of Obstetrics, Gynecology and Reproductive Sciences
Professor of Epidemiology, Senior Scientist, Magee-Women’s Research Institute

Prof. George R. Saade, M.D., University of Texas Medical Branch
Professor, Division Chief Obstetrics & Gynecology

Prof. Baha M. Sibai, M.D., University of Texas Medical School, Visiting Professor

Dr. David Williams, PhD FRCP, University College London
Honorary Senior Lecturer, Maternal & Fetal Medicine, Institute for Women's Health, Faculty of Population Health Sciences

Prof. Simcha Yagel, M.D., Hadassah Medical Center, Israel
Head Division of Obstetrics and Gynecology at Hadassah Medical Center
Head of the Israeli Association of Placental Study



Share Button comm

Investors hp

     Yaky Yanay
     President and COO


Yaky Yanay

Pluristem and CHA Move Forward on Strategic Partnership Agreement; Conclude Mutual Investment of $ 10.4 million

Key Points
• Pluristem issues shares to CHA at a price per share of $ 4.16
• Development and Commercialization of PLX-PAD cells for the Treatment of Peripheral Artery Disease in South Korea

Read more >> 

Share Button comm

 catom 01

catom 03

catom 05

catom 07

catom 09

catom 11

catom 13




catom 02

Share Button